Significant Contracts - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended			12 Months Ended
	May 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-current deferred revenue		$ 12,323,000	$ 14,012,000		$ 12,323,000	$ 14,012,000
Current deferred revenue		3,845,000	4,105,000		3,845,000	4,105,000
Collaboration Expense					110,250,000	130,250,000	$ 110,250,000
Defer option specified cost					110,300,000	110,300,000	110,300,000
A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net profits and net losses								40.00%
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable		200,000,000			200,000,000
Research milestone payment				$ 70,000,000
Business combination, consideration transferred		35,000,000		70,000,000
Revenue						200,000,000
Collaboration Expense					110,300,000	130,300,000	110,300,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable		410,000,000			410,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received					900,000,000
Percentage of net profits and net losses								60.00%
Current payment due					20,000,000
Revenue					0	170,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Non-Ex License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received				100,000,000
Milestone payment receivable		125,000,000			125,000,000			$ 125,000,000
Research milestone payment		10,000,000		$ 70,000,000	25,000,000
Revenue						100,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | March 2023 Diabetes Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue					35,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2019 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential future payments					775,000,000
Vertex Pharmaceuticals Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from letter agreement	$ 43,000,000
Net proceeds from transfer	42.00%
Non-current deferred revenue		12,300,000	12,300,000		12,300,000	12,300,000
Transaction price allocated to remaining performance obligations		12,300,000			12,300,000
Current deferred revenue		$ 0	0		0	0
Reimbursements from research and license agreements					3,200,000	$ 18,000,000	$ 37,800,000
Defer option specified cost			$ 20,000,000
Vertex Pharmaceuticals Inc [Member] | A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received					$ 100,000,000